BNP Paribas Purchases 20,329 Shares of Gilead Sciences, Inc. $GILD

Key Points

• BNP Paribas increased its Gilead Sciences stake by 20.7%, purchasing 20,329 shares to hold 118,671 shares valued at approximately $15.0 million. Institutional investors own 83.67% of the company, with several major firms also adding or initiating positions.
• Wall Street remains broadly positive, with 24 analysts rating Gilead a Buy and five assigning a Hold rating; the consensus is “Moderate Buy” with an average price target of $158.04. However, insiders sold 105,000 shares worth about $14.2 million over the past quarter.
• Gilead reported quarterly revenue of $7.80 billion, ahead of expectations, with revenue up 10.6% year over year, and declared a quarterly dividend of $0.82. Recent FDA and European approvals for HIV and oncology treatments could support future growth.

BNP Paribas boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 20.7% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 118,671 shares of the biopharmaceutical company's stock after buying an additional 20,329 shares during the period. BNP Paribas' holdings in Gilead Sciences were worth $14,992,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. BlackRock Inc. bought a new stake in Gilead Sciences during the 2nd quarter valued at $15,393,785,000. State Street Corp raised its holdings in shares of Gilead Sciences by 1.9% in the 4th quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company's stock valued at $7,393,921,000 after acquiring an additional 1,151,213 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Gilead Sciences by 4.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company's stock worth $3,399,734,000 after buying an additional 1,195,269 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Gilead Sciences by 15.2% during the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company's stock valued at $2,837,948,000 after buying an additional 3,046,688 shares during the last quarter. Finally, Norges Bank purchased a new stake in Gilead Sciences in the 4th quarter worth approximately $2,617,152,000. 83.67% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Anthony Welters sold 18,000 shares of the business's stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the transaction, the director directly owned 12,894 shares of the company's stock, valued at approximately $1,916,306.28. The trade was a 58.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O'day sold 15,000 shares of the firm's stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the sale, the chief executive officer directly owned 592,133 shares of the company's stock, valued at $77,160,851.23. The trade was a 2.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 105,000 shares of company stock valued at $14,238,120. 0.30% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Daiwa Securities Group reduced their price objective on Gilead Sciences from $161.00 to $150.00 and set an "outperform" rating for the company in a research report on Tuesday, May 19th. Leerink Partners lowered Gilead Sciences from an "outperform" rating to a "market perform" rating and dropped their target price for the company from $146.00 to $127.00 in a research report on Tuesday, July 21st. Needham & Company LLC reaffirmed a "buy" rating and issued a $170.00 price objective on shares of Gilead Sciences in a research note on Wednesday, August 5th. Morgan Stanley cut their price objective on shares of Gilead Sciences from $166.00 to $165.00 and set an "overweight" rating on the stock in a report on Monday, July 27th. Finally, HSBC upgraded Gilead Sciences from a "hold" rating to a "buy" rating and upped their price objective for the stock from $133.00 to $155.00 in a research report on Monday, July 6th. Twenty-four investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $158.04.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: The FDA approved Bixlenvo, a once-daily single-tablet regimen combining bictegravir and lenacapavir for virologically suppressed adults with HIV. It is the first and only single-tablet option for patients on complex regimens who cannot use currently available alternatives, potentially expanding Gilead’s HIV franchise and supporting its longer-term lenacapavir strategy. Reuters FDA approval article
• Positive Sentiment: The European Commission approved Trodelvy plus Keytruda for certain first-line metastatic triple-negative breast cancer patients, strengthening Gilead’s oncology portfolio and adding a potential growth opportunity outside its core HIV business. EU Trodelvy approval article
• Neutral Sentiment: Analysts remain broadly constructive, with a consensus “Moderate Buy” rating and an average price target of approximately $158. However, GILD’s strong multi-year advance may have raised expectations and limited the immediate upside from the Bixlenvo approval. Gilead valuation article
• Negative Sentiment: Director Anthony Welters sold 18,000 shares worth about $2.68 million, reducing his position by roughly 58%. The sale occurred under a pre-arranged Rule 10b5-1 plan, making it a limited bearish signal, but it may still weigh modestly on investor sentiment. SEC insider transaction filing

Gilead Sciences Trading Down 2.1%

Shares of GILD stock opened at $145.68 on Friday. The company has a 50 day moving average price of $134.25 and a 200 day moving average price of $136.62. The stock has a market capitalization of $180.64 billion, a P/E ratio of -54.56 and a beta of 0.32. Gilead Sciences, Inc. has a fifty-two week low of $108.46 and a fifty-two week high of $157.29. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping analysts' consensus estimates of ($7.25) by $0.50. The company had revenue of $7.80 billion for the quarter, compared to analysts' expectations of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm's revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter last year, the company earned $2.01 earnings per share. Equities research analysts predict that Gilead Sciences, Inc. will post -0.5 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be given a $0.82 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. Gilead Sciences's payout ratio is currently -122.85%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source